Feasibility of electronic brachytherapy in cervix cancer–A dosimetric comparison of different brachytherapy techniques
Lozares-Cordero, Sergio (Universidad de Zaragoza) ; González Pérez, Victor ; Pellejero-Pellejero, Santiago ; Rodríguez Ruiz, Lucia ; Guinot Rodríguez, José Luis ; Villafranca-Iturre, Elena ; Méndez-Villamón, Agustina (Universidad de Zaragoza) ; Gandía Martínez, Almudena ; Fuentemilla-Urío, Naiara ; Ruggeri, Ricardo
Resumen: Introducción: This study analyzes cases in which electronic brachytherapy (eBT) led to acceptable treatment plans in cervical cancer. Findings were compared with dosimetry values obtained in 192 Ir-based treatments according to the high-risk clinical target volume (HR-CTV) and the disease stage.
Material and methods: We retrospectively analyzed 48 patients with cervical cancer from two centers. The patients were treated with 192 Ir based on MRI. It was possible to use interstitial needles via an Utrecht-type applicator. Dosimetry was simulated using eBT and the parameters D90 and D98 (HR-CTV) and D2cc, D1cc, and D0.1cc (bladder, rectum, and sigmoid colon) were evaluated. The Mann-Whitney U test was used for comparison. The overall cohort of patients was analyzed, as were the sub-cohorts based on stage (FIGO stages I + IIA, IIB and III–IV). Finally, the dosimetry of the eBT plans was evaluated, and the plans obtained were classified as “good”, “acceptable”, or “poor”.
Results: Statistically significant differences were found between the eBT and 192 Ir plans for D98 (HR-CTV), D1cc and D0.1cc (bladder), and D1cc and D0.1cc (sigmoid colon). A total of 31 cases (64.6%) were considered good, seven (14.6%) were considered acceptable, and 10 (20.8%) were considered poor. For volumes < 30 cc, all the plans were good or acceptable; for volumes > 30 cc, 54.3% were good, and 71.4% were good or acceptable. By stage, eBT plans for patients with stage IB–IIA disease were good in 100%, whereas those for patients with stage IIB were good in 70.6% and III–IV disease were good in 50%.
Conclusions: eBT provides appropriate dosimetry for treatment of cervical cancer in selected cases.
Idioma: Inglés
DOI: 10.1016/j.brachy.2022.01.006
Año: 2022
Publicado en: Brachytherapy 21, 4 (2022), 389-396
ISSN: 1538-4721
Factor impacto JCR: 1.9 (2022)
Categ. JCR: RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING rank: 100 / 135 = 0.741 (2022) - Q3 - T3
Categ. JCR: ONCOLOGY rank: 215 / 241 = 0.892 (2022) - Q4 - T3
Factor impacto CITESCORE: 3.6 - Medicine (Q2)
Factor impacto SCIMAGO: 0.741 - Radiology, Nuclear Medicine and Imaging (Q2) - Oncology (Q2)
Tipo y forma: Article (Published version)
Área (Departamento): Área Radiol. y Medicina Física (Dpto. Microb.Ped.Radio.Sal.Pú.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Exportado de SIDERAL (2025-12-19-14:44:33)
Visitas y descargas
Material and methods: We retrospectively analyzed 48 patients with cervical cancer from two centers. The patients were treated with 192 Ir based on MRI. It was possible to use interstitial needles via an Utrecht-type applicator. Dosimetry was simulated using eBT and the parameters D90 and D98 (HR-CTV) and D2cc, D1cc, and D0.1cc (bladder, rectum, and sigmoid colon) were evaluated. The Mann-Whitney U test was used for comparison. The overall cohort of patients was analyzed, as were the sub-cohorts based on stage (FIGO stages I + IIA, IIB and III–IV). Finally, the dosimetry of the eBT plans was evaluated, and the plans obtained were classified as “good”, “acceptable”, or “poor”.
Results: Statistically significant differences were found between the eBT and 192 Ir plans for D98 (HR-CTV), D1cc and D0.1cc (bladder), and D1cc and D0.1cc (sigmoid colon). A total of 31 cases (64.6%) were considered good, seven (14.6%) were considered acceptable, and 10 (20.8%) were considered poor. For volumes < 30 cc, all the plans were good or acceptable; for volumes > 30 cc, 54.3% were good, and 71.4% were good or acceptable. By stage, eBT plans for patients with stage IB–IIA disease were good in 100%, whereas those for patients with stage IIB were good in 70.6% and III–IV disease were good in 50%.
Conclusions: eBT provides appropriate dosimetry for treatment of cervical cancer in selected cases.
Idioma: Inglés
DOI: 10.1016/j.brachy.2022.01.006
Año: 2022
Publicado en: Brachytherapy 21, 4 (2022), 389-396
ISSN: 1538-4721
Factor impacto JCR: 1.9 (2022)
Categ. JCR: RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING rank: 100 / 135 = 0.741 (2022) - Q3 - T3
Categ. JCR: ONCOLOGY rank: 215 / 241 = 0.892 (2022) - Q4 - T3
Factor impacto CITESCORE: 3.6 - Medicine (Q2)
Factor impacto SCIMAGO: 0.741 - Radiology, Nuclear Medicine and Imaging (Q2) - Oncology (Q2)
Tipo y forma: Article (Published version)
Área (Departamento): Área Radiol. y Medicina Física (Dpto. Microb.Ped.Radio.Sal.Pú.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. Exportado de SIDERAL (2025-12-19-14:44:33)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Radiología y Medicina Física
Record created 2025-12-19, last modified 2025-12-19